CIK 0000882095
- Large accelerated filer
GILEAD SCIENCES, INC.
Sign in to watch- Ticker
- GILD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943047598
- Phone
- +1 650-574-3000
- Business address
- 333 LAKESIDE DR, FOSTER CITY, CA, 94404
- Former names
- GILEAD SCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $36,996,096
- in 12 filings, $37.0M under 10b5-1 plans
Net −$36,996,096. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-28 | Kramer Kelly A. Director | Option exercise 10b5-1 | +2,805 | $81.00 | $227K | 4,144 |
| 2025-11-28 | Kramer Kelly A. Director | Sale 10b5-1 | −2,805 | $127.10 | $357K | 1,339 |
| 2025-11-28 | Kramer Kelly A. Director | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −2,805 | 0 | ||
| 2025-11-26 | Kramer Kelly A. Director | Option exercise 10b5-1 | +2,806 | $81.00 | $227K | 4,145 |
| 2025-11-26 | Kramer Kelly A. Director | Sale 10b5-1 | −2,806 | $127.11 | $357K | 1,339 |
| 2025-11-26 | Kramer Kelly A. Director | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −2,806 | 2,805 | ||
| 2025-11-17 | Mercier Johanna Chief Commercial Officer | Option exercise 10b5-1 | +25,000 | $66.64 | $1.7M | 135,193 |
| 2025-11-17 | Mercier Johanna Chief Commercial Officer | Sale 10b5-1 | −25,524 | $125.83 | $3.2M | 109,669 |
| 2025-11-17 | Mercier Johanna Chief Commercial Officer | Sale 10b5-1 | −2,476 | $126.26 | $313K | 107,193 |
| 2025-11-17 | Mercier Johanna Chief Commercial Officer | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −25,000 | 73,110 | ||
| 2025-11-17 | Dickinson Andrew D Chief Financial Officer | Sale 10b5-1 | −2,500 | $125.23 | $313K | 154,555 |
| 2025-11-12 | Telman Deborah H EVP, Corporate Affairs & GC | Option exercise 10b5-1 | +17,181 | $75.12 | $1.3M | 60,857 |
| 2025-11-12 | Telman Deborah H EVP, Corporate Affairs & GC | Sale 10b5-1 | −17,181 | $124.00 | $2.1M | 43,676 |
| 2025-11-12 | Telman Deborah H EVP, Corporate Affairs & GC | Option exercise 10b5-1 | +35,965 | $60.75 | $2.2M | 79,641 |
| 2025-11-12 | Telman Deborah H EVP, Corporate Affairs & GC | Sale 10b5-1 | −35,965 | $122.30 | $4.4M | 43,676 |
| 2025-11-12 | Telman Deborah H EVP, Corporate Affairs & GC | Option exercise 10b5-1 | +500 | $60.75 | $30K | 44,176 |
| 2025-11-12 | Telman Deborah H EVP, Corporate Affairs & GC | Sale 10b5-1 | −500 | $122.90 | $61K | 43,676 |
| 2025-11-12 | Telman Deborah H EVP, Corporate Affairs & GC | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −17,181 | 37,799 | ||
| 2025-11-12 | Telman Deborah H EVP, Corporate Affairs & GC | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −35,965 | 12,655 | ||
| 2025-11-12 | Telman Deborah H EVP, Corporate Affairs & GC | Option exercise · Non-qualified Stock Option (Right to Buy) 10b5-1 | −500 | 12,155 |
Page 12 of 30 · 599 trades